Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lupin denosumab vs Prolia in postmenopausal osteoporosis
jRCT2031230117Phase 3Recruiting
- Sponsor
- DNAVEC
- Start
- Jun 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of denosumab in osteoporosis (2 arms), sponsored by DNAVEC. Primary endpoint: Percent change from baseline in BMD at lumbar spine at Month 12. Started Jun 2023; status: recruiting.
02
Drugs
denosumab
03
Conditions
osteoporosis
Beyond the preview
Go deeper on jRCT2031230117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230117.